BTK inhibitors, such as ibrutinib, acalabrutinib, and zanubrutinib, are currently being used in clinical trials for hematologic malignancies, including B cell lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma, with promising results. The gene discussed is BTK; the disease is B-cell non-Hodgkin lymphoma.